Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.0.1310251
European Journal of Endocrinology, Vol 131, Issue 3, 251-257
Copyright © 1994 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zenobi, P. D
Right arrow Articles by Froesch, E R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Zenobi, P. D
Right arrow Articles by Froesch, E R.

Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A

Peter D Zenobi, Yvonne Glatz, Annamarie Keller, Susanne Graf, Silvia E Jaeggi-Groisman, Walter F Riesen, Eugen J Schoenle and E Rudolf Froesch

Zenobi PD, Glatz Y, Keller A, Graf S, Jaeggi-Groisman SE, Riesen WF, Schoenle EJ, Froesch ER. Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A. Eur J Endocrinol 1994;131:251–7. ISSN 0804–4643

Severe insulin resistance type A is due to mutations in the insulin receptor gene and is characterized by glucose intolerance or diabetes mellitus, despite extreme hyperinsulinemia, virilization and acanthosis nigricans. At present, there is no therapy for this condition. Recently, we showed that glucose levels in three such patients are promptly lowered by an iv bolus of recombinant human insulin-like growth factor I (rhIGF-I). In the present study, we investigated two of these rare patients again and determined fasting and postprandial glucose, insulin, C-peptide, proinsulin and lipid levels during five control, five treatment and three wash-out days while on a constant diet. Treatment consisted of 2 x 150 µg rhIGF-I/kg sc per day, which elevated total IGF-I levels 4.5-fold above the control. Fasting glucose levels (days 1–5) in the two patients were 9.6±1.3 and 9.2 ± 1.2 mmol/l, respectively, and fell to 4.4±0.4 and 5.1±0.5 mmol/l on treatment days 8–10. Fasting insulin (2950±450 and 690±125 pmol/l), C-peptide (2217±183 and 1317±235 pmol/l) and proinsulin control levels (125±35 and 66±0 pmol/l) also decreased by ~65% during rhIGH-I treatment, as did the respective postprandial levels. Lipid levels hardly changed at all. In conclusion, IGF-I appears to correct partially some metabolic sequelae of severe insulin resistance and may, hence, be used as a new therapeutic agent.

E Rudolf Froesch, Department of Internal Medicine, University Hospital, Rämistrasse 100, 8091 Zurich, Switzerland




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
S. A. Kaplan and P. Cohen
REVIEW: The Somatomedin Hypothesis 2007: 50 Years Later
J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4529 - 4535.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. McDonald, R. M Williams, F. M Regan, R. K Semple, and D. B Dunger
IGF-I treatment of insulin resistance
Eur. J. Endocrinol., August 1, 2007; 157(suppl_1): S51 - S56.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
S. Jain, D. W. Golde, R. Bailey, and M. E. Geffner
Insulin-Like Growth Factor-I Resistance
Endocr. Rev., October 1, 1998; 19(5): 625 - 646.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 European Society of Endocrinology.